Metabolic effects of the association Berberis aristata/Silybum marianum: a preliminary double-blind, placebo-controlled study in obese patients with type 2 diabetes

Guarino, Giuseppina; Corte, Teresa Della; Sofia, M.; Carbone, Lucia; Marino, Giampiero; Martedì, Emilia; Gentile, Sandro

doi:10.1007/s13749-015-0052-7

Cited by 20 publications

(35 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After assessment, three studies were excluded because lacking of a control group receiving placebo ( n = 3; Appendix A). Finally, five studies were eligible and then included in the systematic review and meta‐analysis (Derosa et al, ; Derosa et al, ; Derosa et al, ; Guarino et al, ; Guarino et al, ). The study selection process is shown in Figure .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic effect of berberine–silymarin association: A meta‐analysis of randomized, double‐blind, placebo‐controlled clinical trials

Fogacci

Grassi

Rizzo

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

The aim of this study is to assess the impact of a combination of berberine and silymarin on serum lipids and fasting plasma glucose (FPG) through a systematic review of literature and meta‐analysis of the available randomized, double‐blind, placebo‐controlled clinical trials (RCTs). A systematic literature search in SCOPUS, PubMed‐Medline, ISI Web of Science, and Google Scholar databases was conducted up to October 2, 2018, in order to identify RCTs assessing changes in plasma concentrations of total cholesterol (TC), triglycerides (TG), high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C) and FPG during treatment with berberine and silymarin in combination. Two review authors independently extracted data on study characteristics, methods, and outcomes. Quantitative data synthesis was performed using a random‐effects model. We identified five eligible RCTs, with 497 subjects overall included. Berberine and silymarin combination treatment exerted a positive effect on TC (mean difference [MD]: −25.3, 95% CI [−39.2, −11.4] mg/dl; p < 0.001), TG (MD: −28, 95% CI [−35.3, −20.6] mg/dl; p < 0.001), HDL‐C [MD: 6, 95% CI [3.2, 8.8] mg/dl; p < 0.001), LDL‐C (MD: −29.1, 95% CI [−39.7, −18.6] mg/dl; p < 0.001), and FPG (MD: −7.5, 95% CI [−13, −1.9] mg/dl; p = 0.008). The present findings suggest that the coadministration of berberine and silymarin is associated with an advantageous improvement in lipid and glucose profile, suggesting the possible use of this nutraceutical combination in order to promote the cardiometabolic health.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The BBR–silymarin association use, in particular, is supported by a correct pharmacological background (Di Pierro et al, ; Di Pierro et al, ) and has been specifically tested in some well‐designed clinical trials (Derosa et al, ; Derosa, D'Angelo, & Maffioli, ; Derosa, Romano, D'Angelo, & Maffioli, ; Guarino et al, ; Guarino et al, ).…”

Section: Introductionmentioning

confidence: 99%

Metabolic effect of berberine–silymarin association: A meta‐analysis of randomized, double‐blind, placebo‐controlled clinical trials

Fogacci

Grassi

Rizzo

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Of 19 studies, 10 were in favor of controls, of which 5 were significant. Of these, three were of great significance: Guarino et al, 30 Pirillo et al, 38 and Wei et al 32 with ES values of 1.70 (1.31-2.09), 1.12 (0.63-1.60), and 1.10 (0.55-1.65), respectively, indicating great effect according to the Cohen scale.…”

Section: Effects On Ldl Cholesterolmentioning

confidence: 99%

“…Among the 12 significant studies (favor experimental), 3 were of particular interest: Guarino et al, 30 Jun et al, 35 and Pirillo et al 38 with ES = -2.64 (-3.10 to -2.18), -2.54 (-3.51 to -1.58), and -1.87 (-2.42 to -1.33), respectively.…”

Section: Effects On Triglyceridesmentioning

confidence: 99%

See 1 more Smart Citation

Berberine and Dyslipidemia: Different Applications and Biopharmaceutical Formulations Without Statin-Like Molecules—A Meta-Analysis

Bertuccioli

Moricoli

Amatori

et al. 2020

Journal of Medicinal Food

View full text Add to dashboard Cite

The aim of this study was to analyze the efficacy of berberine taken alone or in other formulations (with silymarin or other mixtures) on dyslipidemia through a systematic review of the literature and a meta-analysis. A systematic investigation was conducted on 19 studies that were selected based on inclusion and exclusion criteria. Both controlled trials (n = 12) and cross-sectional trials (n = 7) were included. The following formulations were examined: berberine used alone (n = 5), berberine combined with silymarin (n = 8), and other mixture containing berberine (n = 6). A meta-analysis was performed using a fixed-effects model and meta-regression. Total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, highdensity lipoprotein (HDL) cholesterol, and triglycerides were considered. Moreover, possible associations of each parameter with age and the dose and duration of the treatment were analyzed. The data obtained showed a significant reduction in TC and LDL cholesterol for each formulation. A reduction in triglycerides was also observed for both TC and LDL but with a smaller impact. As regards HDL, a slight increase was observed, but it was not statistically significant. The formulation of berberine in association with silymarin was found to have the greatest impact on TC, LDL, HDL, and triglycerides. The greater efficacy of the formulation consisting of berberine associated with silymarin can probably be accounted for by the fact that the latter increases the bioavailability of berberine. However, it is necessary to carry out further clinical studies to better define the efficacy of the treatment and which patients show the best response.

show abstract

Berberine as a potential autophagy modulator

Mohammadinejad

Ahmadi

Tavakol

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Today, pharmacognosy is considered a valuable science in the prevention and treatment of diseases. Among herbals, Berberine is an isoquinoline alkaloid found in the Berberis species. Surprisingly, it shows antimicrobial, antiviral, antidiarrheal, antipyretic, and anti‐inflammatory potential. Furthermore, it diminishes drug resistance in cancer therapy and enhances tumor suppression in part through autophagy and cell cycle arrest mechanisms. In the present review, we discuss the effect of berberine on diverse cellular pathways and describe how berberine acts as an autophagy modulator to adjust physiologic and pathologic conditions and diminishes drug resistance in cancer therapy.

show abstract

Metabolic effects of the association Berberis aristata/Silybum marianum: a preliminary double-blind, placebo-controlled study in obese patients with type 2 diabetes

Cited by 20 publications

References 35 publications

Metabolic effect of berberine–silymarin association: A meta‐analysis of randomized, double‐blind, placebo‐controlled clinical trials

Metabolic effect of berberine–silymarin association: A meta‐analysis of randomized, double‐blind, placebo‐controlled clinical trials

Berberine and Dyslipidemia: Different Applications and Biopharmaceutical Formulations Without Statin-Like Molecules—A Meta-Analysis

Berberine as a potential autophagy modulator

Contact Info

Product

Resources

About